Authors: Lewis J, Walker AS, Castro H, et al. Published in: J Infect Dis. 2011;205(4):548-556 Background Effective therapies and reduced AIDS-related morbidity and mortality have shifted the focus in pediatric…
Authors: The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Published in: Lancet Infectious Diseases. April: 2011, 273-283 Background Children with HIV will be on antiretroviral therapy (ART) longer than adults, and therefore the…
Authors: Paediatric European Network for Treatment of AIDS (PENTA) Published in: Antivir Ther. 2010;15(3):297-305. Background Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are…
Authors: Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. Published in: Clinical Pharmacology and Therapeutics, 2010, 87(3):294-302. Abstract The establishment of a rationale for determining…
Authors: Sefe D, Klein N, Mosconi I, Ricci E, Castro, H (nee Green), Jacobsen M, Bernardi S, Pillay D, Gibb DM, and De Rossi A, on behalf of the PENTA…
PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children Published in: XVIII International AIDS Conference, 22nd July 2010,…
Authors: Paediatric European Network for Treatment of AIDS. Published in: AIDS. 2010;24(2):231-241. Objective To evaluate clinical, immunological and virological consequences of CD4-guided antiretroviral therapy (ART) planned treatment interruptions (PTIs) compared with continuous therapy in…
Authors: Jacqz-Aigrain, Farrelly L, Compagnucci A, Harrison L, Zhao W, Hamadache D, Welch S, Wintergerst U, Firtion G, Burger D Published in: CROI 2009. February 8-11, 2009. Palais des Congres…
Authors: Zhao W, Farrelly L, Compagnucci A, Harrison L, Jacqz-Aigrain E, Hamadache D, Welch S, Wintergerst U, Burger D on behalf of the PENTA Trial Steering Committee . Published in:…
Authors: Harrison L, Hamadache D, Bunupuradah T, Mazza A, Ramos Amador JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Farrelly L, Riault Y, Lallemant…
Authors: Gibb DM, Compagnucci A, Green H, Lallemant M, et al. Published in: Journal of the International AIDS Society 2008, 11(Suppl 1):O21 (10 November 2008)
Authors: Cressey TR, Green H, Khoo S, Treluyer J-M, Compagnucci A, Saidi Y, Lallement M, Gibb DM, Burger D. Published in: Clin Infect Dis 2008. 15;46(10):1601-8 Background The optimum strategy…
Authors: Compagnucci A, Saïdi Y, Harper L, Blanche S, Gabiano C, de José Gomez I, Notheis G, Gibb DM, Giaquinto C and Faye A for the PENTA 7 committees Published…
Authors: Gibb DM, Green H, Saidi Y, et al; on behalf of PENTA 5. Published in: AIDS.2007;21(8):947-955 Objective To describe the long-term efficacy over 5 years of regimens including combinations…
Authors: LeProvost M, Green H, Flynn J, et al; on behalf of the PENTA 13 study group. Published in: Pediatr Infect Dis J. 2006;25(6):533-7 Background Data on adherence to and…
Authors: Aboulker J-P, Babiker A, Bacheler L, et al. On behalf of the PENTA 8 study group Published in: Antivir Ther. 2006;11(7):857-867 Objective To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological…